TransMolecular was a biotech company located in Birmingham, Alabama.
[1] TransMolecular, Inc. engaged in discovering, developing, and commercializing therapies for glioma, metastatic brain tumors, and cancers.
It developed TM601, a synthetically-produced polypeptide that was derived from scorpion venom, which is used to specifically target tumors in the treatment of cancer.
[3][4] In March 2011, TransMolecular's assets were purchased by Morphotek, a subsidiary of the Japanese pharmaceutical company Eisai.
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub.